Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
PHASE1
Substudy 02B is part of a larger research study where researchers are looki...
Status
Completed
Location
The Angeles Clinic and Research Institute ( Site 2009)
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
PHASE1
Substudy 03B is part of a larger research study that is testing experimenta...
Status
Active Not Recruiting
Location
University of California at San Francisco ( Site 3008)
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
PHASE2
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL)...
Status
Completed
Location
The University of Arizona Cancer Center - North Campus ( Site 2216)
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
PHASE1
This is a phase I/II multicenter, open-label umbrella platform study that w...
Status
Completed
Location
Liga Norte Riograndense Contra o Câncer ( Site 2303)
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
PHASE1
Substudy 02C is part of a larger research study that is testing experimenta...
Status
Completed
Location
The Angeles Clinic and Research Institute ( Site 3009)
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
PHASE1
This study is a substudy being conducted under one pembrolizumab umbrella m...
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
PHASE2
In this study, participants with high risk non-muscle-invasive bladder canc...
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
PHASE1
This study is a rolling arm study of pembrolizumab in combination with inve...
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
PHASE3
The purpose of this study is to assess the safety and efficacy of coformula...